Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds

We present herein a compilation and trend analysis of human i.v. pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data. This data set provides the drug metabolism scientist with a robust and accurate resource suitable for a number of applications, including in silico modeling, in vitro-in vivo scaling, and physiologically based pharmacokinetic approaches. Clearance, volume of distribution at steady state, mean residence time, and terminal phase half-life were obtained or derived from original references exclusively from studies utilizing i.v. administration. Plasma protein binding data were collected from other sources to supplement these pharmacokinetic data. These parameters were analyzed concurrently with a range of simple physicochemical descriptors, and resultant trends and patterns within the data are presented. Our findings with this much expanded data set were consistent with earlier described notions of trends between physicochemical properties and pharmacokinetic behavior. These observations and analyses, along with the large database of human pharmacokinetic data, should enable future efforts aimed toward developing quantitative structure-pharmacokinetic relationships and improving our understanding of the relationship between fundamental chemical characteristics and drug disposition.

[1]  Franco Lombardo,et al.  In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. , 2009, Journal of medicinal chemistry.

[2]  S Oie,et al.  Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.

[3]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[4]  Michael Mayersohn,et al.  A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. , 2006, Journal of pharmaceutical sciences.

[5]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[6]  Keith W Ward,et al.  A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[7]  R J Riley,et al.  The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. , 2006, Current drug metabolism.

[8]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[9]  Malcolm Rowland,et al.  Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[10]  M Paul Gleeson,et al.  Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. , 2007, Journal of medicinal chemistry.

[11]  Taravat Ghafourian,et al.  QSPR models for the prediction of apparent volume of distribution. , 2006, International journal of pharmaceutics.

[12]  Dennis A. Smith Physicochemical Properties in Drug Metabolism and Pharmacokinetics , 2007 .

[13]  Franco Lombardo,et al.  A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.

[14]  Ulf Norinder,et al.  Prediction of ADMET Properties , 2006, ChemMedChem.

[15]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[16]  Keith W Ward,et al.  Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. , 2005, Journal of pharmaceutical sciences.

[17]  Sitarama B. Gunturi,et al.  In Silico ADME Modeling 3: Computational Models to Predict Human Intestinal Absorption Using Sphere Exclusion and kNN QSAR Methods , 2007 .

[18]  Franco Lombardo,et al.  Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. , 2004, Journal of medicinal chemistry.

[19]  J. Kremer,et al.  Drug binding to human alpha-1-acid glycoprotein in health and disease. , 1988, Pharmacological reviews.

[20]  M Paul Gleeson,et al.  In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.

[21]  Gary W. Caldwell,et al.  Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data? , 2004, European Journal of Drug Metabolism and Pharmacokinetics.

[22]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[23]  Christopher A Evans,et al.  EXTRAPOLATION OF PRECLINICAL PHARMACOKINETICS AND MOLECULAR FEATURE ANALYSIS OF “DISCOVERY-LIKE” MOLECULES TO PREDICT HUMAN PHARMACOKINETICS , 2006, Drug Metabolism and Disposition.

[24]  Franco Lombardo,et al.  Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. , 2002, Journal of medicinal chemistry.

[25]  R J Riley,et al.  Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. , 2007, Current drug metabolism.

[26]  U. Fagerholm,et al.  Prediction of human pharmacokinetics – evaluation of methods for prediction of volume of distribution , 2007, The Journal of pharmacy and pharmacology.

[27]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[28]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[29]  I Mahmood,et al.  Interspecies allometric scaling: prediction of clearance in large animal species: part II: mathematical considerations. , 2006, Journal of veterinary pharmacology and therapeutics.

[30]  Han van de Waterbeemd,et al.  Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..

[31]  I Mahmood,et al.  Interspecies allometric scaling. Part I: prediction of clearance in large animals. , 2006, Journal of veterinary pharmacology and therapeutics.

[32]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[33]  David F. V. Lewis,et al.  Baseline Lipophilicity Relationships in Human Cytochromes P450 Associated with Drug Metabolism , 2003, Drug metabolism reviews.

[34]  Z H Israili,et al.  HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡ , 2001, Drug metabolism reviews.

[35]  Keith W Ward,et al.  A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[36]  P. Sluijs,et al.  The influence of binding to albumin and α1-acid glycoprotein on the clearance of drugs by the liver , 1987, Pharmaceutisch Weekblad.

[37]  W. Daniel,et al.  Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. , 1997, Pharmacology & toxicology.

[38]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.